Toll Free: 1-888-928-9744

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2016

Published: Apr 20, 2016 | Pages: 270 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2016" provides an overview of Pre-Diabetes/Impaired Glucose Tolerance clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials 15 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials 19 Clinical Trials by Phase in E7 Countries 20 Clinical Trials in E7 Countries by Trial Status 21 Clinical Trials by Phase 22 In Progress Trials by Phase 23 Clinical Trials by Trial Status 24 Clinical Trials by End Point Status 25 Subjects Recruited Over a Period of Time 26 Clinical Trials by Sponsor Type 27 Prominent Sponsors 28 Top Companies Participating in Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials 30 Prominent Drugs 32 Latest Clinical Trials News on Pre-Diabetes/Impaired Glucose Tolerance 33 Apr 04, 2016: Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo 33 Clinical Trial Profile Snapshots 34 Appendix 267 Abbreviations 267 Definitions 267 Research Methodology 268 Secondary Research 268 About GlobalData 269 Contact Us 269 Disclaimer 269 Source 270
List of Tables
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Region, 2016* 6 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14 Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 16 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 19 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Phase, 2016* 22 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 29 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 31 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32


List of Figures
Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14 Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 15 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Pre-Diabetes/Impaired Glucose Tolerance to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 19 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30 Pre-Diabetes/Impaired Glucose Tolerance Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 32 GlobalData Methodology 268

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify